Shares of Outlook Therapeutics slid 7.6% to $0.90 on Thursday as traders cashed in gains from a volatile post-approval rally, raising a harder question: whether the company can afford to capitalize on its biggest-ever regulatory win.

On July 24, the FDA approved the company's eye-injection drug as the first ophthalmic formulation of bevacizumab for treating wet age-related macular degeneration — a leading cause of vision loss in older adults. The company is targeting the roughly $8.5 billion U.S. anti-VEGF retina market. The stock surged on the news, but has now round-tripped much of those gains, falling from a July 27 close of $1.06 back to $0.90.

  • The Approval Is Real, but the Treasury Is Nearly Empty. Outlook held roughly $7.7 million in cash against $50.9 million in total liabilities, with a quarterly net loss of $4.5 million on revenue of just $1.4 million as of March 31. One analyst downgraded the stock to "Hold," citing acute cash constraints, the urgent need for a funding partnership to support a U.S. launch, and heavy competition from entrenched therapies. Without fresh money, the company cannot credibly build a sales force.

  • Nasdaq Compliance Is Back on the Knife's Edge. After receiving a delisting warning in February for trading below $1.00 for 30 consecutive days, the company regained compliance in late June. But at $0.90, the stock is once again below that threshold. Shareholders already approved a potential 1-for-10 to 1-for-50 reverse stock split and an increase in authorized shares to 600 million — tools that could preserve the listing but further dilute existing holders.

  • Twelve Years of Exclusivity Means Nothing Without Capital. The approval is expected to carry 12 years of reference product exclusivity , a powerful shield against copycat drugs. Commercial launch has already begun in Germany, Austria, and the U.K. , providing a small proof-of-concept. Yet European revenue of $1.4 million quarterly barely dents the $4.5 million quarterly cash burn.

  • Earnings on August 14 Will Be the Next Flashpoint. The company reports fiscal Q3 results on August 14 , where investors will scrutinize the updated cash position and any partnership or financing announcements. H.C. Wainwright recently raised its price target to $1.60 , but that optimism assumes the company solves its funding gap — a bet this stock price says the market isn't yet willing to make.